Fortress Biotech Launches $8 Million Stock Offering
Fortress Biotech, Inc. (Nasdaq: FBIO) is a dynamic force in the biopharmaceutical sector, dedicated to increasing value for its shareholders through smart asset acquisitions and other advancements. Recently, the company made waves by announcing an $8 million registered direct stock offering along with some private placements.
Key Details of the Direct Offering
On September 19th, Fortress Biotech entered into securities purchase agreements with healthcare-focused institutional investors, allowing them to issue a total of 3,939,394 shares of common stock. The purchase price is set at $1.65 per share, reflecting a strategic effort to strengthen the company's financial standing.
Warrants and Additional Investment Opportunities
As part of this offering, Fortress Biotech has also agreed to issue warrants to these investors, enabling them to purchase an equal number of shares of common stock. These warrants have an exercise price of $1.84 per share and come with a six-month activation period, remaining valid for five and a half years.
Insider Investments in Private Placements
In an interesting turn of events, Fortress Biotech’s Chairman, CEO, and President, known as the Insider, purchased 763,359 shares at $1.84, aligning with the closing bid price on the day the agreement was made. This purchase also included warrants that allow the Insider to acquire an equal number of shares, showcasing their confidence in the company's future.
Financial Proceeds and Fund Allocation
The total gross proceeds from these offerings are expected to reach around $8 million. This capital will support various operational needs, such as research and development, clinical trials, and potential product acquisitions. Such financial plans emphasize Fortress Biotech's dedication to innovation and growth.
A.G.P./Alliance Global Partners: Key Placement Agent
A.G.P./Alliance Global Partners has been designated as the sole placement agent for these offerings, which are anticipated to close shortly after this announcement, pending the usual conditions. This collaboration is vital for ensuring a smooth execution of the offerings.
Registration and Compliance Measures
The shares being offered to institutional investors fall under a registration statement on Form S-3, which has already received approval from the Securities and Exchange Commission. This approval highlights Fortress Biotech's commitment to adhering to necessary regulatory standards. Following the direct offering, Fortress will submit a final prospectus supplement with the SEC to maintain transparency and compliance.
About Fortress Biotech
Fortress Biotech, Inc. is at the cutting edge of the biopharmaceutical field, focusing on acquiring and developing assets that support shareholder value. With a varied portfolio that includes seven marketed prescription products and more than 20 active development programs, Fortress is strategically positioned in several important therapeutic areas like oncology and gene therapy. This diverse approach not only encourages innovation but also opens many doors for revenue generation.
Fostering Valuable Collaborations
As part of its mission to enhance growth and reach, Fortress is forming partnerships with top academic institutions and biopharmaceutical companies. Collaborations with organizations like AstraZeneca and Nationwide Children’s Hospital reflect Fortress' commitment to seizing opportunities that can lead to groundbreaking advancements in healthcare.
Frequently Asked Questions
What is the purpose of Fortress Biotech's recent stock offering?
The recent stock offering is designed to raise capital for a variety of operational expenses, including research and development efforts.
Who is the sole placement agent for the offering?
A.G.P./Alliance Global Partners is serving as the sole placement agent for Fortress Biotech's stock offering.
How many shares of common stock were issued?
Fortress Biotech has issued 3,939,394 shares of common stock in this registered direct offering.
What does the private placement involve for the Insider?
The Insider purchased 763,359 shares at $1.84, indicating strong confidence in the company’s future direction.
How does Fortress Biotech comply with regulatory standards?
The shares offered to investors are being issued under a registration statement on Form S-3, which has been approved by the SEC, ensuring compliance with regulatory requirements.
